On this webpage COVID-19 vaccine resources for pharmacists are provided.
Maintained by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP, Bassam Ghanem, Pharm.D., MS, BCPS, and Jeanette Bouchard, Pharm.D.
First Published: 28 December 2020
Last updated: 25 January 2021
On this webpage we are listing links to COVID-19 vaccine resources for pharmacists. You will find general information, links to vaccine-specific content, and links to vaccine literature. This webpage will be periodically updated and the date of updates will be posted.
Have a resource that is not listed yet? Let us know here.
General COVID-19 Vaccine Resources
- World Health Organization – Draft landscape of COVID-19 candidate vaccines
- HHS Public Health Emergency Website
- IDSA COVID-19 Vaccine Website
- NEJM – Covid-19 Vaccine — Frequently Asked Questions
- Immunize.IO COVID Vaccine FAQ
- CDC COVID-19 Vaccines Webpage
- CDC Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States
- CDC Clinician Outreach and Communication (COCA) Calls/Webinars
- Includes recorded webinars, PDF handouts, and sign up option for email alerts
- CDC COVID-19 Webinar and Partner Calls Videos
- CDC webpage on COVID-19 Vaccines and Severe Allergic Reactions
- ACIP COVID-19 Vaccination Recommandations
- Society of Infectious Diseases Pharmacists Videos
- CEP Vaccine Tools Page
Vaccine Use Trackers
- Johns Hopkins Vaccines Tracker
- Our world in Data Coronavirus (COVID-19) Vaccinations
- New York Times Coronavirus Vaccine Tracker (extensive information provided)
Moderna COVID-19 Vaccine (mRNA-1273)
- Moderna COVID-19 Vaccine Webpage
- Includes Fact Sheet for Healthcare Providers and Fact Sheet for Patients
- Moderna Vaccine Expiration Lookup
- CDC Moderna COVID-19 Vaccine Webpage
- CDC Moderna COVID-19 Vaccine Preparation & Administration Summary
- Moderna FDA Briefing Document
- Moderna FDA EUA Letter
- Literature:
PFIZER-BioNTech COVID-19 Vaccine (BNT162b2)
- Pfizer/BioNTech COVID-19 Vaccine Webpage
- Pfizer COVID-19 Resources
- BioNTech COVID-19 Resources
- Pfizer-BioNTech COVID-19 Vaccine Fact Sheet for Recipients
- Pfizer-BioNTech COVID-19 Vaccine Fact Sheet for Healthcare Providers
- Pfizer-BioNTech FDA Briefing Document
- Pfizer COVID-19 Vaccine Webpage
- CDC Pfizer-BioNTech Vaccine Webpage
- CDC Pfizer-BioNTech Vaccine Preparation & Administration Summary
- WHO – Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing
- ASHP – COVID-19 Vaccine Security, Storage, and Handling Resource Guide
- Literature:
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – JAMA
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- Other information
- EU brand name: Comirnaty
- Coined from COVID-19 community, immunity& embeds mRNA in the middle
- Pronounced phonetically as koe mir’ na tee
- International generic name: Tozinameran
- Tozina- is the invented prefix required by the World Health Organization
- -meran is the required suffix for new mRNA Vaccines.
- Pronounced as toe zi na’ mer an
- EU brand name: Comirnaty
AstraZenica COVID-19 Vaccine
Johnson & Johnson COVID-19 Vaccine (Ad26.CoV2.S)
Bharat Biotech COVID-19 Vaccine (BBV152)
COVID-19 Vaccine Literature
Newest additions are towards the top, oldest additions are towards the bottom
- SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement
- Key areas for further research are discussed, including vaccine hesitancy and its effect in the IBD community, the effect of immunosuppression on vaccine efficacy, and the search for predictive biomarkers of vaccine success.
- Looking beyond COVID-19 vaccine phase 3 trials – Nature Medicine
- Vaccinology in the post−COVID-19 era
- mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Approach
- This review summarizes vaccine allergy epidemiology and proposes risk stratification schema: (1) for individuals with different allergy histories to safely receive their first COVID-19 vaccine and (2) for individuals who develop a reaction to their first dose of COVID-19 vaccine.
- Maintaining Safety with SARS-CoV-2 Vaccines
- Viral targets for vaccines against COVID-19
- Designing the Next Generation of Vaccines: Relevance for Future Pandemics
- A guide to vaccinology: from basic principles to new developments
- Reinfection with SARS-CoV-2: Implications for Vaccines
- Evaluating the Efficacy of COVID-19 Vaccines
- ASHP outlines tenets for COVID-19 vaccination rollout
- The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19
- Poses the question: what will the vaccine hesitant do in the face of this pandemic?
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses.
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- The Ad5-vectored COVID-19 vaccine at 5 × 1010 viral particles is safe, and induced significant immune responses in the majority of recipients after a single immunisation.
- Encouraging results from phase 1/2 COVID-19 vaccine trials (Commentary)
COVID-19 Vaccine News Articles / Press Releases
- Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates
- Peak antibodies support Australia’s COVID-19 vaccine strategy
- Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination
- FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
- Extra dose from vials of Comirnaty COVID-19 vaccine
- China approves Sinopharm Covid-19 vaccine for general use
- Oxford University/AstraZeneca vaccine authorised by UK medicines regulator
- AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK
- AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K.
Other Notes
- List-serves from societies such as ASHP, IDSA, and the ACCP ID PRN can serve as valuable resources for practical questions. Memberships required.
Have a resource that is not listed yet? Let us know here.
RECOMMENDED TO YOU
